Using Genetic Polymorphisms to Predict the Efficacy and Toxicity - A Gastric Adenocarcinoma Study
Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study
Sponsor: Mackay Memorial Hospital
Terminated
The budget issues.
Other terminated trials from Mackay Memorial Hospital
Other Gastric Adenocarcinoma trials with similar outcome
This PHASE2 trial investigates Gastric Adenocarcinoma and is currently terminated or withdrawn. Mackay Memorial Hospital leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE2
First recorded
Mar 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mackay Memorial Hospital
- National Cheng-Kung University Hospital
- National Health Research Institutes, Taiwan
- Taipei Veterans General Hospital, Taiwan
- Tri-Service General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .